Introduction
Allogeneic hematopoietic stem cell transplantation (SCT) can cure a substantial number of eligible patients with chronic myeloid leukemia (CML). [1] [2] [3] [4] [5] Relapses occurred in only 10-30% of patients. Increased risk of relapse is associated with a T-cell depletion. [4] [5] [6] To heighten the antileukemic effect of SCT by increasing the intensity of the conditioning regimen has not in fact resulted in improved rates of survival 7 as the therapeutic benefit of SCT is mitigated by high regimen-related toxicity. On the other hand, there is a critically important allogeneic graft-versusleukemia (GvL) effect, 8 and since the 1990s, allogeneic donor lymphocyte infusion (DLI) has been used as a very effective therapeutic modality, especially for patients with CML and residual or recurrent disease following SCT. [9] [10] [11] In recent years, non-myeloablative or reduced-intensity conditioning stem cell transplantation (RIC-SCT), which relies on the post-transplant immune-mediated GvL effect rather than on an intensive pre-transplant conditioning, has been studied as a safer and low-toxicity approach to patients with hematological malignancies. [12] [13] [14] This approach seems to be especially suitable for CML, where the GvL is very strong. 10 So far, few reports describing RIC-SCT in patients with CML have been published. These reports either deal with younger patients, 15 different conditioning regimens 16, 17 or data collected retrospectively from various centers with varied drug dosage. 18 Moreover, the results are strikingly different. Although data exists about the excellent survival rate without molecular relapses, 15 there is nonetheless evidence of a very poor long-term outcome. 19 Since 1998, we have followed a regimen based on busulfan (Bu), fludarabine (Flu) and ATG (Fresenius). Our results prove that this regimen is very well tolerated with low regimen-related toxicity. However, there are some concerns about the anti-leukemic efficiency of this reduced-intensity conditioning. As another new potent treatment for CML is now available -imatinib -and albeit very expensive, we have decided to also analyze retrospectively some pharmacoeconomic cost data about RIC-SCT and compare it with the cost of imatinib treatment. This important side of CML treatment has very rarely been discussed in medical journals so far. During 1998 During -2005 patients with Ph þ CML (median age 50 years; range 15-59) were treated either in the first chronic phase (n ¼ 19), or the accelerated phase (n ¼ 1). These patients were selected for RIC-SCT if they were X50 years old (n ¼ 12); or if they chose the lower intensity transplant after a full and extensive explanation and discussion of the differences between non-myeloablative and myeloablative SCT (n ¼ 8). The median interval from diagnosis to transplant was 149 (range 81-2137) days. All patients signed a consent form before RIC-SCT treatment. Peripheral blood stem cells were used in all but one case, either from a matched sibling donor (n ¼ 19), or from a matched unrelated donor (n ¼ 1). The most important characteristics of the patients are described in Table 1 .
Patients and methods

Patients
Conditioning regimen, graft-versus-host disease prophylaxis and management and supportive care The conditioning regimen consists of intravenous Flu 30 mg/m 2 /day on days À10 to À5, oral Bu (4 mg/kg/day) for 2 (n ¼ 18) or 3 (n ¼ 2) consecutive days ((À7) À6 and À5) and ATG Fresenius at 10 mg/kg/day for 4 consecutive days (À4 to À1) as published previously. 12, 15 Except for the first seven patients, Bu plasma levels were monitored by high-pressure liquid chromatography and the level was kept at 800-1050 ng/ml. Cyclosporin A (CsA) (n ¼ 19) or CsA plus mycophenolate mofetil (n ¼ 1) was used for graftversus-host disease (GvHD) prophylaxis. CsA was tapered from the second or third month after transplantation, according to chimerism status, 22 minimal residual disease (MRD) kinetics and any evidence of GvHD. All patients received antimicrobial prophylaxis with fluconazole, ciprofloxacine (from day À10 to engraftment), cotrimoxazole and high-dose acyclovir (from day À10 to day þ 180; intravenously until day þ 28 at a dose 500 mg/m 2 every 8 h, then 800 mg four times a day). Patients were checked weekly for cytomegalovirus (CMV) infection by CMV-PCR (polymerase chain reaction) until day þ 180. Acute GvHD (aGvHD) was first treated with steroids (2 mg/kg/ day), and in non-responsive cases, pulse cyclophosphamide, ATG or another second-line treatment was administered. Chronic GvHD (cGvHD) was managed by CsA7steroids.
To avoid long-term steroid treatment, mycophenolate mofetil was used.
Response criteria, monitoring of MRD and treatment of relapse A definition of hematological and cytogenetic responses according to Talpaz et al. 23 was used. To detect the presence of residual leukemic cells after RIC-SCT, we used qualitative two-step nested reverse transcriptase (RT)-PCR. 24 For BCR-ABL mRNA expression level monitoring, we employed a quantitative competitive RT-PCR 25 or a quantitative real-time RT-PCR (RQ-RT-PCR); in the latter case, we used RQ-RT-PCR TaqMan system-based method. 26 Molecular remission was defined as a repeated PCR negativity of BCR-ABL.
Molecular relapse was diagnosed when a patient had, over a period of at least 4 weeks, (1) three consecutive samples with BCR-ABL/ABL ratio greater than 0.02%; or (2) three samples with rising ratio, the last two greater than 0.02%; or (3) two samples greater than 0.05% without symptoms of cytogenetic relapse. 5, 27 Before the era of RQ-RT-PCR, molecular relapse diagnosis was based on re-appearance, or rising level of BCR-ABL, both repeatedly confirmed, and on normal cytogenetic and hematological examinations.
In the case of molecular or cytogenetic relapse, the patients were treated either by imatinib, or DLI, depending predominantly on the availability of either treatment modality. We preferred to use DLI in higher degree of relapse or after failure of imatinib. Reduced-intensity allogeneic transplant in chronic myeloid leukemia M Krejci et al
Statistical analysis
Basic statistical characteristics (maximum, minimum, median and mean) were calculated for each of the quantitative parameters (amount of CD34 þ cells in the transplant, day of achieving absolute neutrophil count 40.5 Â 10 9 /l, day of platelet recovery, chimerism on day þ 30, þ 60 and þ 100 and day of achieving complete chimerism). The relationship between the amount of CD34 þ cells in the transplant and the other abovementioned parameters was quantified both by Pearson and Spearman correlation coefficients. The number of cases was counted in distinct categories of qualitative parameters (grade of aGvHD and extent of cGvHD). The impact of the amount of CD34 þ cells in the transplant on these qualitative parameters was tested by one-way analysis of variance. Overall survival and the achievement of complete chimerism were quantified by the Kaplan-Meier estimation of survival function.
Cost analysis
A payment algorithm for health care is quite complicated and consists of the following different categories: (1) hospitalization: one day in the hospital (different for normal ward, intensive care unit or existing deep myelosuppression); plus extra payment for some very expensive drugs, blood products, some more complicated treatment procedures (e.g. dialysis, surgery), some more complicated laboratory analyses (e.g. cytogenetics, PCR) or other examinations (e.g. CT scans, bronchoscopy); (2) ambulatory treatment: clinical examination; plus extra payment for: all drugs, blood products, some more complicated treatment procedures and all laboratory analysis or other examinations. For all transplanted patients, we also calculated the hypothetical costs if they would have been treated with imatinib, 400 mg/day, for the same time period, as following the transplantation. For imatinib, only ambulatory treatment, no disease progression, no complications and regular 3-month visit intervals (incl. some laboratory examinations) were considered. Only the direct health-care costs were calculated. In our study, the data on utility (quality of life or patients preferences) were not collected. Consequently, the full cost-utility analysis (gaining the cost per QALY (quality-adjusted life years)) cannot be provided.
Results
Transplant-related toxicity and hematopoietic recovery
The conditioning regimen was well tolerated by all 20 patients. Grade 3 and 4 WHO non-hematological toxicity was not observed. The majority of patients (16/20) did not experience oral mucositis and were maintained on a normal oral intake; the remaining four patients required supplementary parenteral nutrition. Short episodes of febrile neutropenia were observed in 10 patients (50%) with median duration of 2 days (range: [1] [2] [3] [4] [5] [6] [7] [8] [9] ). Neutrophil engraftment (neutrophils 40.5 Â 10 9 /l) occurred at a median of 17 days (range: 11-28), whereas platelets recovered to 420 Â 10 9 /l at a median of 11 days after transplant (range: 0-19). All 20 patients engrafted. Transfusion requirements were relatively low, with a median of 2 U of packed red blood cells transfused (range: 0-9 U), and a median of 2 platelet units transfused (range: 0-8 U) per patient. No blood products at all were necessary in eight (40%) patients. No transplant-related mortality (TRM) until day þ 100 was observed. No significant correlation between CD34 þ cells in transplant and quantitative characteristics (day of achieving absolute neutrophil count 40.5 Â 10 9 /l; day of platelet recovery; chimerism on the day þ 30, þ 60 and þ 100; day of achieving complete chimerism) was found.
GvHD and infections
The incidence of aGvHD was 55%; grade I þ II and III þ IV occurred in five cases (25%) and six cases (30%), respectively. cGvHD developed in 15 (75%) of the patients; limited and extensive in seven cases (35%) and eight cases (40%), respectively. The amount of CD34 þ cells in the transplant has no significant impact on the development of aGvHD or cGvHD of any grade. Two of the steroidrefractory GvHD patients (developed after transplantation and DLI, respectively) did not respond to any GvHD treatment, and both patients died. In the patient dying from DLI, there was a slow progression, over the period of several months, of the development of molecular, cytogenetic and hematological relapses. Owing to logistical reasons, the intervention was carried out at the time of frank hematological disease with bulk DLI dose. Therefore, we can only speculate that if intervention had occurred earlier, this patient would not have died. Currently, all cGvHD patients are well with their Karnofsky performance index at at least 80, and only four of them are on some mild immunosuppressive therapy not containing steroids (two patients on CsA alone 25 and 250 mg per day, respectively, and two patients on combination therapy CsA and mycophenolate mofetil 1 or 1.5 g per day).
Infectious complications only occurred in 11 patients up to day þ 100. CMV infection was observed in five (25%) patients, all of whom were successfully treated with ganciclovir. Other infectious complications include macroscopic hematuria with BK virus positivity in urine (two cases developing during immunosuppressive therapy for GvHD), bronchitis (two cases) and bronchopneumonia (two cases, without pathogen identification responding to empirical treatment). After day 100, one profoundly immunosuppressed patient, with repeatedly relapsing GvHD, developed severe bronchopneumonia caused by the RS virus and eventually died from generalized adenoviral infection.
Disease response, chimerism relapses and survival The transplantation itself led to an achievement of molecular remission in 14 (70%) of the patients. Five additional patients (25%) achieved complete cytogenetic remission, and one patient (5%) achieved hematological remission. All six patients without molecular remission and with increasing PCR positivity of MRD underwent additional therapy (DLI and/or imatinib); four of them achieved molecular remission after this treatment (see Table 2 ; patients nos. 9, 11, 12 and 15). The total number of infused CD3 þ cells
Reduced-intensity allogeneic transplant in chronic myeloid leukemia M Krejci et al ranged from 1 Â 10 7 to 1 Â 10 8 /kg and was administered on one or more occasions. Imatinib was used in a standard daily dose of 400 mg. Median time to achieve the first complete molecular remission was 189 days after transplantation.
Complete chimerism was achieved on day þ 30, þ 60 and þ 100 in 30%, 45% and 55% of patients, respectively. An achievement of complete donor chimerism was eventually observed in 18 (90%) patients with a median time of 106 days after transplantation (Figure 1) .
Seven patients (35%) relapsed after RIC-SCT, some of them repeatedly. Their first relapses were molecular, cytogenetic and hematological in 5, 1 and 1 case, respectively (Table 2) . Relapses occurred at various intervals after transplantation (5-77 months). No patient had any signs of GvHD at the time of relapse. Patients with relapses were treated with DLI and/or with imatinib (Table 2) , and four out of seven patients again achieved molecular remission. Any treatment with imatinib dramatically increased the costs of the post-transplant drug treatment. In fact, additional anti-leukemic therapy after RIC-SCT (for relapses and/or no achievement of molecular remission) was necessary in 10 (50%) out of 20 patients.
Eighteen out of the 20 patients (90%) survived with a median follow-up of 27 months after the transplant. Fifteen (75%) patients were in molecular remission (10 of them in the first molecular remission), one patient was in complete cytogenetic remission, one patient in cytogenetic relapse and one patient in molecular relapse. Two patients died 5 months after and 22 months after the RIC-SCT, suffering from severe steroid-refractory GvHD with serious infectious complications. The overall survival is shown in Figure 2 . Table 2 Additional anti-leukemic therapy after reduced-intensity allogeneic transplant Case no.
Response after transplantation
Additional anti-leukemic therapy for non-achievement of molecular remission (months after transplantation);
Relapses after transplantation (months)
Additional anti-leukemic therapy after NST for relapse (months after NST); Response Response Reduced-intensity allogeneic transplant in chronic myeloid leukemia M Krejci et al
Cost analysis
The results are summarized in Tables 3 and 4 . As can be seen, the total direct cost of hypothetical imatinib treatment (2 005 117 euro) is higher than the actual total direct cost of transplantation treatment (1 572 880 euro). The main cost drivers of transplantation treatment are hospitalizations, laboratory examinations and drugs for ambulatory treatment. A significant part of the entire amount was spent during the first 12 months. If the patients had been treated with imatinib, the majority of all costs would have been the acquisition cost of the drug alone. Other costs would have been negligible, including the cost of outpatient visits. It seems that RIC-SCT becomes less expensive than imatinib after about 2 years follow-up when one considers direct costs only.
Discussion
Nowadays, there is a dilemma in performing a transplant for patients with newly diagnosed CML which could be well controlled in most cases by imatinib. On the other hand, delaying transplantation for CML can be problematic, as best results are achieved in patients transplanted in the first chronic phase and within the first year of diagnosis. 4, 15 In recent years, RIC-SCT has been shown to yield encouraging results with respect to the reduction of TRM. [12] [13] [14] [15] It offers acceptable toxicity profiles, which are of particular importance in patients older than 45 years of age.
14 We can confirm these findings. The TRM in our group of 20 CML patients was 0% to day þ 100 and TRM up to 1 year after the transplant was 5%. No serious regimen-related acute organ toxicity was found.
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Reduced-intensity allogeneic transplant in chronic myeloid leukemia M Krejci et al of GvHD in our group of patients was relatively high, but seems to be similar to other published RIC-SCT trials. 15, 16, 30 GvHD was the only cause of death in our series. On the other hand, cGvHD positively influenced relapse incidence both in the RIC-SCT setting 31 and in the CML patients who previously had a transplant after conventional conditioning. 32 We believe that this positive effect was also seen after reduced-intensity conditioning regimen had been used in our group of patients, as no patient showed any signs of GvHD at the time of relapse. Further systematic studies are required to determine the efficiency and optimum use of DLI for patients with different kinds of diseases already treated by non-myeloablative stem cell transplantation. Nevertheless, preliminary published data, 33 as well as our experience ( Table 2 ), show that this is a viable treatment option for unsatisfactory response/disease progression and/or persistence of mixed chimerism.
Many reports, albeit not all, 34 describe infections as a serious complication after RIC-SCT. [35] [36] [37] [38] In our series of patients, however, we did not find that infections were a major problem. Mohty et al., 38 using conditioning similar to that used by our group, reported incidences of positive CMV antigenemia 42%, incidences of bacteremia 25% and incidences of fungal infections 8% during the first 6 months post transplant. In our patients, we saw CMV infection in only 25% of patients and did not observe any bacteremia or fungal infection. There are several possible explanations for this finding: (1) they reported having 81% high-risk patients; (2) they did not report using prophylactic highdose acyclovir; (3) bone marrow was used as a graft source in 47% of patients; (4) they used various doses of thymoglobuline instead of ATG Fresenius. Source, dose and the timing of ATG may also significantly influence the final transplantation outcome. 39 A high dose of acyclovir has been shown, in two randomized trials, to have a positive impact on the frequency of CMV infections and even on survival. 40, 41 Long-term outcome of non-myeloablative transplants is unknown and the interpretation of the data published so far is hampered by their heterogeneity. This may in part explain the big differences between the published results. Das et al. using Bu, Flu and ATG (Fresenius) conditioning. It seems that our results are comparable to theirs concerning engraftment, acute regimen-related toxicities, early zero mortality, incidence of GvHD and overall survival. As in our series, they reported three deaths and all were related to GvHD. They also described the rather frequent need of abrupt CsA withdrawal and/or DLI administration (6/24 patients) for mixed chimerism. The main difference compared to our experience is that they did not report any evidence of molecular relapse. The reason for these discrepancies in the results remains elusive. Perhaps it is due to the significantly higher median age of our patients (50 vs 35 years), or due to subtle differences in CsA withdrawal and/or GvHD management. Two other reports used immunoablative conditionings with minimal myelosuppressive potential. 16, 17 Sloand et al. 16 transplanted 12 patients in the first or second chronic phase CML after cyclophosphamide and Flu. Immediately after transplantation, all patients recovered leukemic hematopoiesis as proven by the high leukocyte counts, the bone marrow presence of the Ph chromosome and persistent recipient myeloid chimerism. The majority of patients required further intervention to finally be rid of the disease, including retransplantation after myeloablative conditioning. Four out of five patients in the second chronic phase died in blast crisis. The author concluded that cytoreduction is required to optimize the curative effects of allogeneic SCT for CML. Kerbauy et al. 17 transplanted 24 patients after conditioning comprised of 2 Gy TBI7Flu. Four out of eight patients who were not given Flu experienced graft rejection. With the median follow-up of 36 months, 13 out of 24 patients (54%) were alive. There were five deaths from non-relapse mortality, one during the first 100 days after transplant. The question again arises to the intensity of the conditioning necessary for good post transplant results, while retaining low acute toxicity. De Lima et al. 42 clearly showed in patients with AML or MDS that reduced-intensity conditioning in comparison with nonablative conditioning provided better disease control. Based on our experience with Bu þ Flu þ ATG regimen, to show that slow disease control is not an exception, we have increased the dose of Bu to 12 mg/kg in all patients with myeloid malignancies (CML, AML and MDS). Our first data (not yet published) shows that this dose is extraordinarily well tolerated.
Financial aspects of all cancer therapeutic modalities are very important. In the case of CML, where two completely different new treatment options are available -RIC-SCT and imatinib -more precise pharmacoeconomic data might help in the consideration to which treatment to choose. It should be emphasized, however, that all the economical data must be seen in the context of a given country and health-care system. Only a few published reports have been dealing with the economical aspects of CML treatment taking imatinib also into account. 21, 43 Dalziel et al. 43 performed a very detailed analysis of the cost-effectiveness of imatinib compared with interferon-alpha and hydroxyurea based on published data from large studies. They did not deal, however, with the cost-effectiveness of imatinib compared with transplantation and stated that more detailed economic studies was required in this area.
Skrepnek et al. 21 showed via mathematic simulation and using the Markov model that imatinib was both less costly and more efficacious than allogeneic bone marrow transplantation using matched unrelated donors in the 2-year treatment horizon for a 35-year-old man with CML in the chronic phase. For their analysis, they used data from published trials, and direct medical costs were collected from available references or derived from expert opinion. In our work, we calculated the direct costs for RIC-SCT and imatinib from a hospital perspective.
Within these settings, it seems that RIC-SCT procedure may be cheaper than imatinib treatment. This fact emerges especially in long-term survivors, where the differences are immense. Our data is only a part of the full costeffectiveness or cost-utility analysis. To provide any standard comparison based on the cost per QALY, then data on utility (quality of life) and life expectancy for RIC-SCT and imatinib should be included. This should be a subject of future studies, as well as a calculation of indirect costs (productivity loss, disability). However, we see even this limited data (direct costs) to be ultimately of interest and could shed further light on the policies of the transplant centers in some countries. In the Czech Republic, for example, there is firstly an economic limitation and further political control as to how much can be spent on the entire health-care system. Private financing for expensive treatments as well as commercial health insurance is virtually non-existent. Hence, all physicians and hospitals work within financial limits that are rarely surpassed. Furthermore, the system continuously and dramatically changes, including financial limitations, and oddly enough, there are also separate limitations on hospitalizations and outpatient drug subscriptions. This also influences the final selection of either treatment option. Therefore, direct health-care costs are an important factor in the final decision and deeper insights from a societal perspective are rare. The main differences between our study and the study published by Skrepnek et al. 21 which could explain the different results, are probably as follows: longer follow-up and predominant usage of grafts from HLA-identical sibling in a majority of our patients and different health-care systems.
In conclusion, RIC-SCT after conditioning with Flu þ Bu (8-12 mg/kg) þ ATG (Fresenius) seems to be a very well-tolerated treatment procedure with encouraging results in CML. In some countries, it can be a less expensive treatment option than imatinib when one considers direct costs only. However, very careful, sophisticated and logistically demanding long-term monitoring, and early intervention in the case of molecular relapses are necessary. We believe that this treatment should still be a part of the initial treatment considerations in all CML patients, especially those with a HLA-identical sibling donor.
